Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of using artificial intelligence and genomic data to revolutionize oncology drug discovery, has announced a significant addition to its Board of Directors. Dr. Lee T. Schalop, a seasoned leader in the biotechnology sector with over two decades of experience, has been appointed to the board. Dr. Schalop's background includes co-founding and serving as the CEO of Oncoceutics Inc., a company renowned for its work in developing targeted therapies for solid tumors, such as HK327M-mutant gliomas, before its acquisition by Chimerix Inc. (NASDAQ: CMRX) and later by Jazz Pharmaceuticals.
The appointment of Dr. Schalop is a strategic move for Lantern Pharma, as highlighted by CEO Panna Sharma. Dr. Schalop's expertise in neurooncology and his track record in strategic transactions are expected to complement Lantern's AI-powered drug development platform and its CNS cancer pipeline at Starlight Therapeutics. This collaboration aims to fast-track the company's precision oncology programs, offering hope for patients with limited treatment options. Dr. Schalop expressed his enthusiasm for joining Lantern Pharma, emphasizing the potential to leverage AI in discovering novel therapies for challenging cancers.
Lantern Pharma's innovative approach to drug discovery, powered by its proprietary RADR(R) platform, which utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms, has set a new benchmark in the industry. The company's ability to advance drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years, at a cost of approximately $2.5 million per program, underscores the transformative potential of AI in oncology drug development. For more details on Lantern Pharma's groundbreaking work, visit https://ibn.fm/bDXDZ.
This strategic appointment underscores Lantern Pharma's commitment to leveraging cutting-edge technology and expert leadership to address some of the most pressing challenges in oncology. The integration of Dr. Schalop's deep industry knowledge and Lantern's AI-driven platform heralds a new era of innovation in cancer treatment, promising to deliver more effective therapies to patients faster than ever before. For the latest updates on Lantern Pharma's progress, investors and interested parties can visit https://ibn.fm/LTRN.
